Chimerix Investor Conference Presentation Deck

Serious Adverse Events 12 Any SAE¹ Gastrointestinal disorders Nausea Vomiting General disorders and administration site conditions Disease progression Nervous system disorders Brain oedema Encephalopathy Headache Respiratory, thoracic and mediastinal disorders Dyspnoea INTERNA Vascular disorders Embolism Pulmonary embolism Any attribution, N (%) 25 (50%) 2 (4%) 2 (4%) 2 (4%) 2 (4%) 4 (8%) 3 (6%) 2 (4%) 2 (4%) 2 (4%) ¹Specific preferred terms occurring in more than one patient are listed; 25 patients had at least one SAE ²Possibly related per investigator assessment; unlikely related per sponsor assessment Related, N (%) 1 (2%) 0 0 0 0 0 0 0 0 1 (2%)²

View entire presentation